Ikena Oncology, Inc. (IKNA)

USD 1.55

(-4.32%)

Market Cap (In USD)

74.8 Million

Revenue (In USD)

9.16 Million

Net Income (In USD)

-68.16 Million

Avg. Volume

137.01 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.22-2.3
PE
-
EPS
-
Beta Value
0.485
ISIN
US45175G1085
CUSIP
45175G108
CIK
1835579
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Mark Manfredi Ph.D.
Employee Count
-
Website
https://ikenaoncology.com
Ipo Date
2021-03-26
Details
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.